If consummated, the marriage will also give AbbVie access to Aliada's MODEL platform for delivering large-molecule drugs across the blood-brain barrier (BBB). The Boston biotech said the platform ...

AbbVie Inc. took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing. The ...

AbbVie stock jumped Friday after the pharma titan hiked its full-year outlook on the back of strength from its immunology powerhouses Skyrizi and Rinvoq. The duo now completely outearn AbbVie's ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AbbVie (NYSE:ABBV) is scheduled to announce its earnings on Friday, April 25, 2025. Currently, the company holds a market capitalization of $307 billion. Over the past twelve months, AbbVie ...

AbbVie expects full-year earnings in the range of $12.09 to $12.29 per share. AbbVie shares have increased 1.5% since the beginning of the year, while the S&P’s 500 index has declined nearly 7%.

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

It was Abbvie who finished the half the stronger with three answered points including a brace from Brian Reape. Half Time Abbvie 1-05 1-04 Boston Scientific Scores were hard to come by in the ...